# Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

> **NCT01302847** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 181 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** DTG film-coated tablets
- **DRUG:** DTG granules for suspension
- **DRUG:** DTG dispersible tablets
- **DRUG:** DTG dispersible tablets
- **DRUG:** DTG dispersible tablets

## Key facts

- **NCT ID:** NCT01302847
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-20
- **Primary completion:** 2021-01-20
- **Final completion:** 2023-10-18
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302847, "Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01302847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*